Esperion
The Lipid Management Company

Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website
Sign-up for Email alerts

| NASDAQ: ESPR | |
|---|---|
| Last Trade: | 44.74 |
| Trade Time: | 4:00 PM ET Aug 18, 2017 |
| Change: | -0.24 (-0.534%) |
| Day Range | 43.79 - 45.89 |
| 52-Week Range | 9.40 - 57.38 |
| Volume | 859,945 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... (more)

## Stock Performance




## Press Releases [ View all ]

*Aug 11, 2017*
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

*Aug 9, 2017*
Esperion Prices Public Offering of Common Stock

*Aug 8, 2017*
Esperion Announces Proposed Public Offering of Common Stock

*Aug 8, 2017*
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results

*Aug 8, 2017*
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin

## Financials [ View all ]

Second Quarter Financial Results

*Feb 22, 2017*
Annual Report (10-K)

*Mar 6, 2017*
Proxy Statement (DEF 14A)

*Aug 8, 2017*
Quarterly Report (10-Q)

*May 4, 2017*
Quarterly Report (10-Q)

*Nov 3, 2016*
Quarterly Report (10-Q)